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Figure 2. Diagram of potention function of alloreactive CD4+ T ceIIs in dCBT
patients.
Figure 1. IL-22 induces epithelial regeneration ex vivo.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78S58(4-1BB), a member of the tumor necrosis factor receptor
(TNFR)-family, as a means to identify a more encompassing
compartment of alloreactive T cells in addition to IFN-g
secretion. Consistent with our previous report, no signiﬁcant
CD4+ IFN-g secreting population was detected in the PBMCs
obtained from day 14 post-CBT patient blood after
stimulation with LCLs from the non-engrafting unit (Fig 1).
However, the frequency of CD4+ cells that express CD137
(median, 8.86%; range, 1.39-16.7%) was signiﬁcantly higher
than the frequency of IFN-g secreting cells (median, 2%;
range, 0.2-4.39%) when stimulated with LCLs from the
non-engrafting unit (p<0.0001). Moreover, the CD137
expressing CD4+ T cell population was speciﬁc for allogeneic
stimulation with signiﬁcantly higher CD137 expression
frequency when stimulated with LCLs from the non-
engrafting unit as compared to stimulation with LCLs from
the engrafting unit (p<0.0001, Fig 1). In summary, this study
provides the ﬁrst clear evidence that a distinct population of
CD137+IFN-g- CD4+ alloreactive T cells is present in the
peripheral blood of patients undergoing dCBT and are
involved in the GvG effects observed after dCBT. Functional
deﬁnition of this distinct population (Th2 or Th17) might
disclose an important role of GvG interactions in the
regulation of GVHD, the prevention of graft rejection, and the
maintenance of GVL effects as hypothesized by Fig 2.42
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Little is known about regulation of the intestinal stem cell
(ISC) compartment in gut GVHD. We have found that
Interleukin-22 (IL-22) is important for ISC recovery afterBMT. However, the mechanism and speciﬁc epithelial targets
of IL-22 are poorly understood.
Using clinically modeled LP into C57BL/6 (B6) minor anti-
gen-mismatched BMT (H-2b into H-2b), we found that daily
treatment with recombinant murine IL-22 (4ug IP starting D7
post-BMT) led to reduced GVHD pathology in small intestine
(SI) and large intestine (LI) three weeks after transplant
(p<0.001) without altering GVL or alloreactivity. Mice treated
with IL-22 (no pharmacologic immunosuppression) main-
tainedmore Lgr5+ ISCs and demonstrated signiﬁcantly greater
ISC proliferation (p<0.01). Although IL-22 is thought to
regulate Paneth cells (PCs), and PCs make up the SI stem cell
niche, IL-22-mediated protection of ISCs was not due to niche
augmentation, as PC numbers, PC-derived growth factors
(EGF, Wnt3), and stroma-derived growth factors (R-spondin
3) were all unchanged after IL-22 administration. However,
antimicrobial proteins Reg3b and Reg3g were both upregu-
lated in IL-22-treatedmice (p<0.01), suggesting enhanced gut
barrier function.
To evaluate direct effects on epithelial regeneration, we
performed intestinal organoid cultures in the presence of
IL-22. Organoids generated from wild-type B6 crypts
demonstrated substantially increased size after seven days of
culture with IL-22 (SI p<0.001, Fig. 1; LI p<0.05).
Co-culturing crypts with innate lymphoid cells, potent
producers of IL-22 in vivo, also led to increased organoid size.
IL-22 signiﬁcantly increased organoid EdU incorporation and
new crypt budding, and serial passaging with IL-22 greatly
increased organoid expansion, suggesting that IL-22 could
augment ISC regeneration. IL-22 receptor staining further
indicated a direct effect of IL-22 on ISCs rather than the stem
cell niche, as PCs were found to express very little IL-22
receptor (Fig. 2). Indeed, IL-22 led to expansion of the Lgr5+
ISC pool within SI organoids (Fig. 2), activated STAT3
phosphorylation in Lgr5+ cells, and increased size and
budding of organoids cultured from puriﬁed SI ISCs (p<0.05).
To investigate potential for clinical translation, we next
tested a recombinant human IL-22 dimer/Fc fusion molecule
(F-652, Generon Corp., Shanghai). F-652 signiﬁcantly
increased the size of SI and LI organoids (p<.05). Using the LP
into B6 BMT model described above, we also found that
treatment with F-652 (100 mg/kg subQ every other day
starting D7 post-BMT) signiﬁcantly improved both systemic
GVHD scoring and survival (Fig. 3).
In summary, we found that IL-22 can bridge immune
function and tissue regeneration by acting directly on
epithelial stem cells. IL-22 therapy may represent a
novel approach to promote intestinal recovery in GVHD
patients without increasing post-transplant immunode-
ﬁciency.
Figure 2. ISCs are expanded by IL-22 in vitro.
Figure 3. In vivo administration of F-652 (rhlL-22) rescues mice from GVHD.
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Landmark analyses at 3 and 6 months for subsequent FFS, NRM and survival.
FFS after 3 mos NRM after
3 mos
Surv
3 mo
NIH-calculated CR+PR vs. SD+PD P¼0.51 P¼0.55 P¼0.
Clinician-reported CR+PR vs. SD+PD HR 0.34,
95% CI 0.22-0.52,
P<0.001
P¼0.84 P¼0.
Clinician-reported Improvement vs.
Stable vs. Worsening
P<0.001 P¼0.57 P¼0.
Patient-reported Improvement vs.
Stable vs. Worsening
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One of the greatest challenges to research progress in
chronic graft-versus-host disease (GVHD) is lack of validated
response criteria for complete response (CR), partial
response (PR), stable disease (SD) and progressive disease
(PD). We compared four methods of assessing chronic GVHD
response (calculated response proposed in the 2005 NIH
chronic GVHD Consensus conference or clinician-reported
CR+PR vs. SD+PD, and clinician- or patient-reported
improvement, stability or worsening) for their ability to
predict three subsequent clinical outcomes at 3 and 6 mos:
failure free survival (FFS), deﬁned as survival without
addition of a new treatment, relapse or death; non-relapse
mortality (NRM); and survival. Data were derived from 575
adult patients in a prospective observational study
conducted by the Chronic GVHD Consortium at 9 centers.
342 (59%) were enrolled within 3 months (mos) of chronic
GVHD diagnosis. The median time to enrollment was 11.9
mos after transplant (range 2.9 - 294), median FU after
enrollment was 44 mos (range 0.9-76), and 149 (26%) have
died. At enrollment, 302 (53%) had moderate severity cGVHD
and 220 (38%) were classiﬁed as severe. Landmark analyses
were performed for patients who were alive and had not
failed at the three-month or six-month visit (Table). We
found that clinician-reported response at 3 mos wasival after
s
FFS after 6 mos NRM after 6 mos Survival after 6 mos
51 HR 0.73, 95%
CI 0.53-1.02,
p¼0.06
P¼0.24 HR 0.64, 95%
CI 0.39-1.02,
P¼0.06
47 HR 0.61, 95%
CI 0.44-0.85,
P¼0.004
P¼0.06 HR 0.55, 95%
CI 0.36-0.85,
P¼0.007
82 P¼0.28 P¼0.62 P¼0.60
36 P¼0.08 P¼0.33 P¼0.44
